184 related articles for article (PubMed ID: 29199854)
1. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
Olsen J; Jensen KF; Olesen DS; Knoop A
J Comp Eff Res; 2018 May; 7(5):411-419. PubMed ID: 29199854
[TBL] [Abstract][Full Text] [Related]
2. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
[TBL] [Abstract][Full Text] [Related]
4. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
[TBL] [Abstract][Full Text] [Related]
5. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
6. Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden.
Valachis A; Sundqvist M; Carlsson L; Li B; Chiesa F; Uhde M; Sanglier T
Future Oncol; 2019 Aug; 15(23):2733-2741. PubMed ID: 31306041
[No Abstract] [Full Text] [Related]
7. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
[No Abstract] [Full Text] [Related]
8. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
[TBL] [Abstract][Full Text] [Related]
9. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
[No Abstract] [Full Text] [Related]
11. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
12. Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.
Heng JE; Raman S; Wong ZY; Beh VJN
Daru; 2024 Jun; 32(1):67-76. PubMed ID: 37903943
[TBL] [Abstract][Full Text] [Related]
13. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
15. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
[TBL] [Abstract][Full Text] [Related]
17. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
Van den Nest M; Glechner A; Gold M; Gartlehner G
Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients.
González García J; Gutiérrez Nicolás F; Ramos Díaz R; Nazco Casariego GJ; Viña Romero MM; Llabres Martinez M; Llanos Muñoz M; Batista López JN; Jiménez Sosa A; Ceballos Lenza I; Cruz Jurado J
Ann Pharmacother; 2020 Aug; 54(8):775-779. PubMed ID: 31971005
[No Abstract] [Full Text] [Related]
20. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
